A novel solution specifically designed to address a major challenge in heart valve therapy.
NEWS & PRESS RELEASE
Presentation of Saturn at TCT – September 2022
Our technology has been presented at 2022 TCT held on September 16-19 in Boston, MA. Specifically, Dr. Paolo Denti, MD held a presentation about our Trans-apical FHU Study: 2-Years follow up, showing solid and effective data. Dr. Lauren S. Ranard, MD illustrated a...
Presentation of Saturn at TVT 2022 – June 2022
Our technology has been presented at 2022 TVT held on June 8-10 in Chicago, IL. Specifically, Dr. Paolo Denti, MD, spoke about "Trans-apical FHU Study: 1-Year follow up". Full video available here.
InnovHeart appoints David Wilson as Chief Executive Officer
Industry Leader to Guide Company and the Saturn TMVR Programin its Next Phase of Growth InnovHeart s.r.l. announced today the appointment of David James Wilson, an experienced healthcare and medical device executive as Chief Executive Officer of the company and...
InnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement System
InnovHeart and Grand Pharmaceutical Group Enter Into an Exclusive License Agreement to Develop and Commercialize the Saturn TMVR Device in Greater China Milan, January 27, 2022 - InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement...
“Learning and innovation go hand in hand.
The arrogance of success is to think that what you did yesterday
will be sufficient for tomorrow.”